Navigation Links
Chemical tests of cell growth enter third dimension

Ohio State University researchers have developed two new technologies for measuring cell growth in the laboratory.

The first patent-pending technology provides a way for researchers to easily tell if cancer cells in the laboratory are responding to an anti-cancer drug. The second -- because it tests several sets of cells at once -- allows for the simultaneous testing of different dosages, or the effect of a single drug on different kinds of cells taken from the body.

Shang-Tian Yang, professor of chemical and biomolecular engineering at Ohio State, and his colleagues described the two technologies Wednesday and Thursday at the American Chemical Society Fall National Meeting in San Francisco.

For more than a decade, Yang's team has been developing three-dimensional methods for growing cells for laboratory testing. His fibrous-bed bioreactor (FBB) is a device that allows cells to grow in natural 3D bundles. In the body, cells cling to supportive tissues as they grow; inside the FBB, they cling to strands of polyester fibers.

For the first of the two new technologies, Yang took the basic concept behind the FBB and combined it with laboratory testing methods that normally only grow cells in two dimensions.

Such tests are normally done on cells in trays containing many tiny wells. Each well contains a growth medium and some cells, and a protein that will cause growing cells to fluoresce. Researchers test a drug by adding it to a well. If the cells continue to fluoresce, that means that the cells are still reproducing, and the drug isn't effective at controlling growth.

The problem is how to measure the amount of fluorescence, to quantify how much the cells are growing. Fluorescing cells don't look very bright in the well, because they grow as a thin film layer that is essentially two-dimensional. Researchers get around this problem by removing the cells from the well and counting them one by one under a microscope.

I t's a long and tedious process.

"Our idea is very simple," Yang said. "We wanted to intensify the signal so that it could be read inside the well, by cultivating the cells in three dimensions."

Yang and his team created a device that uses standard well plates in a new way. In one well, they plant cells on one of their 3D scaffolds. The surrounding eight wells contain only growth medium.

The 3D glob of cells in the middle well glows brighter than a 2D film, due to a specific optical effect, Yang said. The surrounding empty cells provide a darker background that lets the fluorescence signal be measured even more easily.

"You can use this as a device to monitor a drug's effect, whether you want to stimulate or inhibit cell growth," Yang said. "We have used it on colon cancer cells and mouse embryonic stem cells. And in both cases, we found a very good relation between cell growth and fluorescence intensity."

The device can be used with standard well plates, though nine wells are required for each test instead of one. He and his team are expanding the technology from 96-well plates to 384-well plates, and are working on their own custom plate design.

There is an advantage to using more wells: The eight empty wells supply nutrients to the cells in the middle well, so tests can run for up to two weeks without researchers having to replenish the growth medium.

"If you replenish the medium, you could essentially grow cells indefinitely," Yang said.

The second new technology to come from Yang's lab is a microfluidics platform that allows for testing of many types of cells or drug dosages at once. Tiny pipes connect wells that contain cells growing in 3D. The drug to be tested is pumped from a common reservoir into the pipes.

Each well could receive a different dosage of the same drug. Or, researchers could plant cells from different organs in each well, and see how each kind of cell reacts to the same d osage -- a quick way to detect a drug's potential side effects on the body.

"The trick is to use one pump for everything, and control the fluid distribution though all the channels," Yang said. While he has worked out an initial design, he would like to join with a commercial microfluidics manufacturer to develop the technology further.

The university is expecting to license both technologies.


'"/>

Source:Ohio State University


Related biology news :

1. Chemicals in tattoo inks need closer scrutiny
2. Roots Engage in Underground Chemical Warfare
3. Chemical Engineer Kao Explores Antibiotic Synthesis With DNA Chips
4. Chemical band-aid prevents heart failure in mice with muscular dystrophy
5. Chemical compound inhibits tumor growth, size in new mouse study
6. T-rays: New imaging technology spotlighted by American Chemical Society
7. Chemical warfare agent detection technology used to treat lung disease
8. Chemical guidance of T cells leads to immunologic memory and long-term immunity
9. Chemical signaling helps regulate sensory map formation in the brain
10. Chemical in many air fresheners may reduce lung function
11. Chemicals in brown algae may protect against skin cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/27/2017)... --  Strategic Cyber Ventures , the industry,s first cybersecurity ... million investment in  Polarity , the first commercial human ... based and is led by cybersecurity veterans Tom ... Gula , also a longtime cybersecurity veteran and founder ... A round of funding. This new funding will be ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... 23, 2017  GlobeImmune, Inc. today announced it has ... of 12,835,490 shares of its common stock to NantCell, ... connection with the sale of its common stock, NantCell ... issue to GlobeImmune 200,000 shares, an estimated $2.0 million ... "We are pleased to enter into this strategic agreement ...
(Date:3/23/2017)... March 23, 2017 NetworkNewsWire Editorial Coverage  ... Cancer ... significant strain on health care systems, in terms of costs ... so too does the development of innovative and efficient therapies ... Among the many types of cancer treatments, a growing number ...
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer Monitoring Technologies ... Dr. Sigmund “Sig” Floyd as Vice President ? Global Business Development. Dr. Floyd ... , “Dr. Floyd’s career has spanned 30 years in the chemicals and equipment ...
(Date:3/22/2017)... 2017  UBM and the Massachusetts Medical Device ... partnership and the third annual Massachusetts Medtech Week. Massachusetts ... st Annual MassMEDIC Conference held in conjunction ... 2017. MassMEDIC will feature a ... and CEO, Scott Whitaker , at its ...
Breaking Biology Technology: